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CTI 2012 manuscript ‘Is High Dose Vitamin D Harmful?’ January 2013 
AUTHORS RESPONSE TO TWO LETTERS TO THE EDITOR 
Minisola S et al, CTI-13-0001 ‘Intermittent High doses of vitamin D: A need for further studies?’ 
Minisola and colleagues 1 comment that the two RCTs (Sanders et al 2and Smith et al 3) lack 
important information concerning the distribution of risk factors for falls (cognitive impairment, drug 
use, alcohol use etc) in the two arms. Sanders et al reported that at baseline the prevalence of risk 
factors for falls and fractures, and previous fractures since the age of 50 years, were similar in the 
vitamin D and placebo groups. Smith et al reported that previous fractures were similar in the two 
groups.  Since more than 90% of fractures occur after a fall 4 it is highly unlikely that a difference in 
baseline prevalence of risk factors for falls existed in either study.  Furthermore, participants in both 
studies were randomised only if mentally competent to participate. Similar scores of mental well-
being parameters and the use of antidepressants at baseline has been reported in the vitamin D and 
placebo groups in the Sanders et al study 5. 
Most importantly, both trials had over 2,000 participants so random allocation would ensure that 
any common characteristic, such as falls in subjects in their late 70s, would be evenly distributed. 
This is a fundamental characteristic that ranks the RCT as the highest level of clinical evidence, only 
out-ranked by meta-analysis of multiple RCTs.  
Minisola et al suggest that if it is fluctuation in serum 25(OH)D, rather than the peak value 
reached, that is associated with increased falls/fracture risk, then the problem might be overcome 
by using intramuscular injection, which causes a slower increase in plasma 25(OH)D than oral 
administration.  We do not disagree that fluctuation may be the problem but the fact that similar 
adverse effects on older women were seen in both RCTs, despite the different routes of 
administration, suggests that the cause is more complex than simply the route of administration or 
the rate of rise of 25D.  
In both studies, 25(OH)D levels three to four month post-dose were only modestly 
(approximately 20%) elevated above pre-dose levels.  In the Smith et al study the very small number 
assayed (n= 30 treated, 13 placebo) reduced the power to detect a significant difference in 25(OH)D 
at 4 months.  However, there was a greater (35.7%) increase in 1,25-dihydroxyvitamin D, which was 
significant (P<0.002).  
Minisola and colleagues confirm the urgent need for RCTs with physical outcomes as primary 
endpoints. Study design that adhere to the CONSORT guidelines and are appropriately randomised 
and adequately powered would be balanced in risk factors for falls and fractures between treatment 
and placebo groups. 
 
Grant W, CTI-12-0347 “Is high dose vitamin D harmful?” 
We agree that Grant 6 has identified common limitations of prospective cohort studies. Our paper 
states that we do not attempt to present a “balanced” view of potential risk/benefit ratio of vitamin 
D supplementation but have summarised results from studies using intermittent, high-doses of 
vitamin D, with particular attention to those finding evidence of adverse effects. 
Grant states the limitation that in many prospective studies serum 25(OH)D was measured at the 
time of enrolment with long follow-up periods for cancer outcomes. We agree the vitamin D status 
taken years prior to the diagnosis, may be irrelevant but these population-based studies are 
hypothesis-generating and the associations need to be tested using gold standard randomised 
placebo-controlled study design. Grant also correctly points out the potential flaws of case-control 
studies where vitamin D status is compared between the groups with and without the disease. The 
cases may have taken measures to improve their vitamin D status as a consequence of the diagnosis.   
We would welcome the conduct of “properly-designed” vitamin D RCTs.  However, Grant’s 
guidelines for such are speculative and raise additional questions including: (1) determining the 
“concentration-health outcome relation” would rely on high-quality well-controlled data that are not 
available.  Furthermore, any such data derived from observational studies will be problematic 
because the relation may be quite different in an interventional study when the concentrations are 
dynamic; (2) the rate and magnitude of the increase in serum 25(OH)D levels may be critical; (3) due 
to individual variation, a set dose may not achieve a concentration “near the upper end” – many will 
be well above, or below this.  Therefore, the dose will need to be titrated in each participant causing 
issues with blinding and logistics; (4) at which time-points after dosing should the concentrations be 
measured?; (5) finally, in the very large, long-term studies required to determine clinical endpoints 
the cost performing multiple biochemical assays is a major impediment. 
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